We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Kodiak Sciences Inc. (KOD) Down 12.7% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for Kodiak Sciences Inc. (KOD - Free Report) . Shares have lost about 12.7% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Kodiak Sciences Inc. due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Kodiak Sciences Q4 Loss Widens, Eye Candidate in Focus
Kodiak Sciencesreported a fourth-quarter 2021 loss per share of $1.79, much wider than the Zacks Consensus Estimate of a loss of $1.29. The company reported a loss of 97 cents per share in the year-ago quarter.
Kodiak Sciences currently does not have any approved product in its portfolio. As a result, the company is yet to generate revenues.
Quarter in Detail
Research and development expenses were $75.6 million in the quarter, significantly up from $37.4 million reported in the year-ago period. The increase was driven by higher clinical activities related to KSI-301.
General and administrative expenses were $17.4 million, up 83.1% on a year-over-year basis, driven by higher headcount and stock-based compensation expenses.
As of Dec 31, 2021, Kodiak Sciences had cash worth $731.5 million compared with $799.2 million as of Sep 30, 2021.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in estimates revision.
The consensus estimate has shifted -5.68% due to these changes.
VGM Scores
Currently, Kodiak Sciences Inc. has a poor Growth Score of F, however its Momentum Score is doing a lot better with a C. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of this revision indicates a downward shift. Notably, Kodiak Sciences Inc. has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Kodiak Sciences Inc. (KOD) Down 12.7% Since Last Earnings Report?
It has been about a month since the last earnings report for Kodiak Sciences Inc. (KOD - Free Report) . Shares have lost about 12.7% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Kodiak Sciences Inc. due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Kodiak Sciences Q4 Loss Widens, Eye Candidate in Focus
Kodiak Sciencesreported a fourth-quarter 2021 loss per share of $1.79, much wider than the Zacks Consensus Estimate of a loss of $1.29. The company reported a loss of 97 cents per share in the year-ago quarter.
Kodiak Sciences currently does not have any approved product in its portfolio. As a result, the company is yet to generate revenues.
Quarter in Detail
Research and development expenses were $75.6 million in the quarter, significantly up from $37.4 million reported in the year-ago period. The increase was driven by higher clinical activities related to KSI-301.
General and administrative expenses were $17.4 million, up 83.1% on a year-over-year basis, driven by higher headcount and stock-based compensation expenses.
As of Dec 31, 2021, Kodiak Sciences had cash worth $731.5 million compared with $799.2 million as of Sep 30, 2021.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in estimates revision.
The consensus estimate has shifted -5.68% due to these changes.
VGM Scores
Currently, Kodiak Sciences Inc. has a poor Growth Score of F, however its Momentum Score is doing a lot better with a C. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of this revision indicates a downward shift. Notably, Kodiak Sciences Inc. has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.